Showing results (251-260 of 261) with videos related to

Sort By:
Pageof 27
Blood Cancer Journal|October 3, 2015
The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemiaM Díaz-Beyá, S Brunet, J Nomdedéu, et al.
Leukemia & Lymphoma|January 19, 2018
Bone marrow VEGFC expression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with survivalVicent Guillem, Marisa Calabuig, Salut Brunet, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 9, 2019
Prognostic factors in patients with primary cutaneous anaplastic large cell lymphoma: a multicentric, retrospective analysis of the Spanish Group of Cutaneous LymphomaR Fernández-de-Misa, B Hernández-Machín, A Combalía, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|March 29, 2002
Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patientsJ Bladé, J F San Miguel, M Fontanillas, et al.
Blood|September 6, 2019
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myelomaLaura Rosiñol, Albert Oriol, Rafael Rios, et al.
Nature Medicine|February 5, 2025
Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trialSaad Z Usmani, Thierry Facon, Vania Hungria, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 20, 2021
Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM ExperiencePaula Rodriguez-Otero, Maialen Sirvent, Ana Pilar González-Rodríguez, et al.
Clinical and Experimental Dermatology|October 11, 2017
First-line treatment in lymphomatoid papulosis: a retrospective multicentre studyR Fernández-de-Misa, B Hernández-Machín, O Servitje, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 10, 2022
Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple MyelomaLuis-Esteban Tamariz-Amador, Paula Rodríguez-Otero, Ana Jiménez-Ubieto, et al.
Haematologica|November 30, 2023
Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detectionSunil Lakhwani, Laura Rosiñol, Noemí Puig, et al.
Pageof 27